9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more


AxioMx Inc
688 East Main Street
Suite2A
Branford, CT 06405

Phone: 203-208-1918
Fax: 203-433-4068
Website: http://axiomxinc.com

Contact(s)
jverney@axiomxinc.com

General Information
AxioMx, founded in 2012 and based in Branford, Connecticut is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMx’s unique platform of proprietary phage display libraries, library screening, and affinity maturation methods provides the technical foundation of the company. The company offers a full range of custom antibody discovery and development services for the research and diagnostic market places.

Using its proprietary phage display libraries and “rapid liquid” approach to screening and affinity maturation, AxioMx has shortened typical monoclonal antibody development times from 4 to 6 months to as little as 8 weeks. The proprietary AxioMx platforms enable fast delivery of highly specific, high affinity, and reproducible recombinant antibodies that are optimized to work in a desired application. AxioMx antibodies are generated entirely in vitro which enables consistent antibody quality across production batches.

AxioMx services are used in research and diagnostic applications across pharma, biotech, diagnostic, academic and life science organizations. Research groups that need a custom antibody fast as well as an antibody that is optimized for their specific assay will benefit from these services.

Research Activities
AxioMx invests in research activities that will expand its recombinant antibody portfolio and the speed at which it can develop antibodies.

Other Information
Ownership: Private
CT Employees: 12
World Employees: 12

Back